ISOXSUPRINE HYDROCHLORIDE

×

Overview

What is ISOXSUPRINE HYDROCHLORIDE?

Each tablet taken orally contains Isoxsuprine Hydrochloride, USP with the following chemical structure:

Quantitative Ingredient Information:

Pharmacological Class:

What does ISOXSUPRINE HYDROCHLORIDE look like?

What are the available doses of ISOXSUPRINE HYDROCHLORIDE?

Sorry No records found.

What should I talk to my health care provider before I take ISOXSUPRINE HYDROCHLORIDE?

Sorry No records found

How should I use ISOXSUPRINE HYDROCHLORIDE?

Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows:

Oral: 10 to 20 mg, three or four times daily.

What interacts with ISOXSUPRINE HYDROCHLORIDE?

There are no known contraindications to oral use when administered in recommended doses.

Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.

What are the warnings of ISOXSUPRINE HYDROCHLORIDE?

Sorry No Records found

What are the precautions of ISOXSUPRINE HYDROCHLORIDE?

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

What are the side effects of ISOXSUPRINE HYDROCHLORIDE?

On rare occasion oral administration of the drug has been associated in time with the occurrence of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued.

Although available evidence suggests a temporal association of these reactions with Isoxsuprine Hydrochloride, a causal relationship can be neither confirmed nor refuted.

Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrochloride have been used to inhibit pre-term labor.

Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received Isoxsuprine Hydrochloride. Pulmonary edema has been reported in mothers treated with beta stimulants. Isoxsuprine Hydrochloride is neither approved nor recommended for use in the treatment of premature labor.

What should I look out for while using ISOXSUPRINE HYDROCHLORIDE?

There are no known contraindications to oral use when administered in recommended doses.

Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.

What might happen if I take too much ISOXSUPRINE HYDROCHLORIDE?

Sorry No Records found

How should I store and handle ISOXSUPRINE HYDROCHLORIDE?

For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012For prolonged storage, Sandostatin ampuls and multi-dose vials should be stored at refrigerated temperatures 2ºC-8ºC (36ºF-46ºF) and store in outer carton in order to protect from light. At room temperature, (20ºC-30ºC or 70ºF-86ºF), Sandostatin is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. After initial use, multiple-dose vials should be discarded within 14 days. Ampuls should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly.Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, NJ 07936© NovartisT2012-71March 2012Isoxsuprine HCl Tablets, USP 10 mg are white, round, biconvex tablets identified as "I10" debossed on one side and bisected on the other.Isoxsuprine HCl Tablets, USP 20 mg are white, round, biconvex tablets identified as "20" debossed on one side and bisected on the other.Isoxsuprine HCl Tablets, USP 10 mg are white, round, biconvex tablets identified as "I10" debossed on one side and bisected on the other.Isoxsuprine HCl Tablets, USP 20 mg are white, round, biconvex tablets identified as "20" debossed on one side and bisected on the other.

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Non-Clinical Toxicology

There are no known contraindications to oral use when administered in recommended doses.

Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.

On rare occasion oral administration of the drug has been associated in time with the occurrence of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued.

Although available evidence suggests a temporal association of these reactions with Isoxsuprine Hydrochloride, a causal relationship can be neither confirmed nor refuted.

Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrochloride have been used to inhibit pre-term labor.

Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received Isoxsuprine Hydrochloride. Pulmonary edema has been reported in mothers treated with beta stimulants. Isoxsuprine Hydrochloride is neither approved nor recommended for use in the treatment of premature labor.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: